Faculty

Institution

Unit

Venue

Symmans, William F

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Surgical Pathology

William F. Symmans is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on breast cancer biology, pharmacology, and the development of predictive biomarkers for neoadjuvant therapy response. He is internationally recognized for pioneering the Residual Cancer Burden (RCB) index, a validated prognostic tool for event-free survival in breast cancer. His recent work includes a novel statistical framework for surrogate endpoint prediction in neoadjuvant trials, pre-analytical best practices for RNA sequencing from small biopsies, and immune subtyping to identify hormone receptor-positive patients who respond to neoadjuvant immunotherapy, as demonstrated in analyses of the I-SPY2 trial. He also contributed to the DESTINY-Breast11 phase III trial evaluating trastuzumab deruxtecan in HER2-positive early breast cancer.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Symmans, William F

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

breast cancer oncology cancer research cancer care cancer treatment medicinal research radiation oncology cancer biology breast oncology pharmacology clinical research medicine tumor biology pathology cancer genomics cancer imaging surgical oncology cancer management clinical trials molecular cancer oncogenes neoadjuvant chemotherapy cancer immunotherapy cancer genetics anti-cancer agents cancer cells cellular therapy tumor targeting molecular diagnostics cancer risk medical mycology pharmacotherapy gynecologic oncology cancer discovery endocrine oncology gene expression clinical evidence therapeutic efficacy prognosis triple-negative breast cancer surgical pathology histopathology drug targeting vascular biology breast surgery cancer prevention microarray data analysis clinical radiation oncology residual cancer burden cancer detection breast imaging pathologic complete response prognostic biomarkers lymphoid neoplasia gene expression profiling neoadjuvant therapy novel therapies rna biology drug trials clinical pathology cytopathology neoadjuvant systemic therapy transcriptomics technology breast carcinoma cancer growth ductal carcinoma breast cancer patients hematological malignancies clinical pharmacology gene expression profiles estrogen receptor neoadjuvant treatment inflammatory breast cancer tumor-infiltrating lymphocytes endocrine therapy breast cancer subtype

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1401: A Novel Statistical Framework for Surrogate Endpoint Prediction of Survival in Neoadjuvant Breast Cancer Trials.. Cancer Research (2026)

cancer caresurvival analysisbiostatisticsbreast cancerstatisticsoncologyprognosisbreast oncology

Pre-Analytical Best Practices for Rna Sequencing From Small Biopsies and Cytologic Specimens. Molecular Diagnosis & Therapy (2026)

genomicstranscriptomelong-read sequencingomicsnext-generation sequencinghigh throughput sequencinggeneticssmall biopsiesmolecular diagnosticsbiomedical analysispre-analytical best practicespathologycytologic specimens

Adams Contribute to Triple Negative Breast Cancer via Mtorc1 Pathway: Targeting Adam-Mtor Axis Improves Efficacy. Cancer Letters (2025)

molecular cancermtorc1 pathwaytherapeutic targetsmolecular cell biologybreast oncologynegative breast cancerbreast cancermolecular biologyoncogenescancer cellsadam-mtor axiscancer biologytumor biologycell biology

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. Journal of Clinical Oncology (2025)

Otto Metzger FilhoKarla BallmanJordan CampbellMinetta LiuJennifer LigibelMark WatsonEveline ChenLili DuDaniel StoverLisa CareyAnn PartridgeJeffrey KirshnerHyman MussClifford HudisEric P. WinerLarry NortonW. Fraser Symmans

novel therapiestherapeutic efficacytumor targetingmedicineadjuvant dose-dense chemotherapybreast cancerjama oncologycancer researchsurgical oncologyurologytumor suppressorscancer immunotherapycancer treatmenttumor biologyimmunologypharmacotherapyoncologyoncogenesmedicinal research

A Pooled Analysis Evaluating Prognostic Significance of Residual Cancer Burden in Invasive Lobular Breast Cancer. npj Breast Cancer (2025)

Rita A. MukhtarSoumya GottipatiChristina YauSara López-TarruellaHelena EarlLarry HaywardLouise HillerMarie OsdoitMarieke van der NoordaaDiane de CrozeAnne-Sophie HamyMarick LaéFabien ReyalGabe S. SonkeTessa G. SteenbruggenMaartje van SeijenJelle WesselingMiguel MartínMaria del Monte-MillánJudy C. BougheyMatthew P. GoetzTanya HoskinVicente ValeroStephen B. EdgeJean E. AbrahamJohn M. S. BartlettCarlos CaldasJanet DunnElena ProvenzanoStephen-John SammutJeremy S. ThomasAshley GrahamPeter HallLorna MackintoshFang FanAndrew K. GodwinKelsey SchwensenPriyanka SharmaAngela M. DeMicheleKimberly ColeLajos PusztaiMi-Ok KimLaura J van ’t VeerDavid CameronLaura J. EssermanW. Fraser Symmans

pooled analysiscancer researchresidual cancer burdenbiostatisticsbreast cancerprognostic significanceprognostic evaluationbreast oncology

Aso Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-Spy2 Clinical Trial. Annals of Surgical Oncology (2025)

breast surgeryradiologyradiation oncologysurgical oncologyaso visual abstractoncologybreast cancerneoadjuvant chemotherapycancer treatmentjama oncologypathologyi-spy2 clinical trialbreast oncology

Aso Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-Spy 2 Clinical Trial. Annals of Surgical Oncology (2025)

surgeryi-spy 2breast surgeryradiologycancer careradiation oncologycancer researchsurgical oncologybreast cancer outcomesclinical trialsoncologybreast canceraso visual abstractbreast oncology

Circulating Tumor Dna (Ctdna) in Patients With Stage 2/3 Hr+Her2-Negative Breast Cancer (Bc) Treated With Neoadjuvant Endocrine Therapy (Net) in the I-Spy2 Endocrine Optimization Pilot (Eop) Trial.. Journal of Clinical Oncology (2025)

Silver AlkhafajiMark Jesus M MagbanuaLaura van t VeerKarthik GiridharMatthew P. GoetzRita MukhtarChristos VaklavasAnthony D. EliasMei WeiGillian L. HirstHope S. RugoLaura Ann HuppertW. Fraser Fraser SymmansAlexander D. BorowskyLamorna Brown SwigartNatsuko OnishiDouglas YeeNola HyltonLaura EssermanJo Chien

endocrine-related cancerscancer researchnovel therapiesgeneticsbreast canceroncologytumor dnaneoadjuvant endocrine therapy

Combination of Predicted Sensitivity to Endocrine Therapy (Set2,3 Index) and the Recurrence Score® in Node-Positive Breast Cancer: Independent Validation in the Pacs-01 Trial. European Journal of Cancer (2025)

endocrine-related cancerscancer carecancer managementradiation oncologycancer discoverybiostatisticsbreast canceroncologyprognostic biomarkersrecurrence score®set2,3 indexcancer riskpredicted sensitivitygynecologybreast oncology

Combined Prognostic Impact of Initial Clinical Stage and Residual Cancer Burden After Neoadjuvant Systemic Therapy in Triple-Negative and Her2-Positive Breast Cancer: An Analysis of the I-Spy2 Randomized Clinical Trial. Breast Cancer Research (2025)

medicineher2-positive breast cancercancer careradiation oncologyresidual cancer burdensurgical oncologybreast canceroncologycancer cellscancer treatmentpathologyinitial clinical stagebreast oncology

1
2
3
4
5
44
10 / page

Symmans, William F

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Surgical Pathology

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Symmans, William F

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1401: A Novel Statistical Framework for Surrogate Endpoint Prediction of Survival in Neoadjuvant Breast Cancer Trials.. Cancer Research (2026)

cancer caresurvival analysisbiostatisticsbreast cancerstatisticsoncologyprognosisbreast oncology

Pre-Analytical Best Practices for Rna Sequencing From Small Biopsies and Cytologic Specimens. Molecular Diagnosis & Therapy (2026)

Adams Contribute to Triple Negative Breast Cancer via Mtorc1 Pathway: Targeting Adam-Mtor Axis Improves Efficacy. Cancer Letters (2025)

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. Journal of Clinical Oncology (2025)

A Pooled Analysis Evaluating Prognostic Significance of Residual Cancer Burden in Invasive Lobular Breast Cancer. npj Breast Cancer (2025)

pooled analysiscancer researchresidual cancer burdenbiostatisticsbreast cancerprognostic significanceprognostic evaluationbreast oncology

breast surgeryradiologyradiation oncologysurgical oncologyaso visual abstractoncologybreast cancerneoadjuvant chemotherapycancer treatmentjama oncologypathologyi-spy2 clinical trialbreast oncology

surgeryi-spy 2breast surgeryradiologycancer careradiation oncologycancer researchsurgical oncologybreast cancer outcomesclinical trialsoncologybreast canceraso visual abstractbreast oncology

endocrine-related cancerscancer researchnovel therapiesgeneticsbreast canceroncologytumor dnaneoadjuvant endocrine therapy

medicineher2-positive breast cancercancer careradiation oncologyresidual cancer burdensurgical oncologybreast canceroncologycancer cellscancer treatmentpathologyinitial clinical stagebreast oncology

1
2
3
4
5
44
10 / page